There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics Inc (NASDAQ:GTHX), Incyte Corp (NASDAQ:INCY) and Epizyme (NASDAQ:EPZM) with bullish sentiments.
G1 Therapeutics Inc (GTHX)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on G1 Therapeutics Inc today. The company’s shares opened today at $39.54.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.9% and a 37.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $77, implying a 94.7% upside from current levels. In a report issued on October 9, H.C. Wainwright also maintained a Buy rating on the stock with a $79 price target.
.
See today’s analyst top recommended stocks >>
Incyte Corp (INCY)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Incyte Corp today. The company’s shares opened today at $65.18, close to its 52-week low of $60.23.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -7.0% and a 33.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Blueprint Medicines.
Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $77.29, implying a 18.6% upside from current levels. In a report released today, Raymond James also upgraded the stock to Buy with a $85 price target.
.
Epizyme (EPZM)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme today. The company’s shares opened today at $8.28, close to its 52-week low of $7.96.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 9.2% and a 50.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $21.25, implying a 156.6% upside from current levels. In a report released today, Roth Capital also maintained a Buy rating on the stock with a $18 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
